Juan Carlos
Hernández Boluda
Publicaciones en las que colabora con Juan Carlos Hernández Boluda (10)
2023
-
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681
-
Should we move to a genomic classification of neutrophilic myeloid neoplasms?
Blood Advances
2022
-
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry
Leukemia Research, Vol. 115
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
2021
-
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Leukemia and Lymphoma
-
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis
Bone Marrow Transplantation, Vol. 56, Núm. 9, pp. 2160-2172
2020
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2017
-
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia
British Journal of Haematology, Vol. 178, Núm. 5, pp. 764-771
2016
-
Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera
European Journal of Haematology, Vol. 96, Núm. 3, pp. 285-290